Indecent Disclosure: The Press Release Balancing Act

May 4, 2011 – 3:57 pm | By Trista Morrison | No comments yet

Sometimes it’s tough for biotechs to figure out what, exactly, constitutes news.

Yesterday, Cell Therapeutics Inc. issued a release stating the FDA had “concluded that accelerated approval of pixantrone NDA 022481 may not necessarily be out of reach based on a single controlled clinical trial.” Not until the second paragraph did readers find out the most important tid-bit: that the FDA had denied their appeal regarding the cancer drug, which received a complete response letter last year.

Meanwhile, Vivus Inc. issued first quarter earnings late Monday, but the piece of news everyone was most interested in – the path forward for obesity drug Qnexa (phentermine/topiramate) following its complete response letter – didn’t emerge until the fourth paragraph.

Other companies seem to think everything they do is newsworthy. The Street’s Adam Feuerstein wrote a funny post yesterday on Cel-Sci Corp.’s apparent need to issue 16 press releases regarding the start of a Phase III trial with immunotherapy Multikine for head and neck cancer:

Another guilty party in this category is Spencer Pharmaceuticals Inc., which issued a string of press releases last fall announcing a dinner with acquirer Al-Dora, then that the dinner had been postponed, and then that the dinner had been confirmed.

While investors might have been interested in a play-by-play of Spencer’s dining plans, if I held the stock, I’d be more curious just how much money they’re spending with PR Newswire.


Post a Comment

You must be logged in to post a comment.

Register To Comment

Please register to comment on the BioWorld Perspectives blog. An email will be sent to you with your login and password information. Please store this for future use. Subscribers to BioWorld publications must also register.